...
首页> 外文期刊>Journal of vascular surgery >The role of uroldnase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis
【24h】

The role of uroldnase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis

机译:uroldnase纤溶酶原激活物和纤溶酶激活物抑制剂-1在实验性深静脉血栓形成中对静脉壁重塑的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Deep vein thrombosis (DVT) resolution instigates an inflammatory response, resulting in vessel wall damage and scarring. Urokinase-plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), are integral components of the fibrinolytic system, essential for venous thrombosis (VT) resolution. This study determined the vein wall response when exposed to increased and decreased plasmin activity.Methods: A mouse inferior vena cava (IVC) ligation model in uPA -/- or PAI-1 -/- and their genetic wild types (B6/SvEv and C57/BL6, respectively) was used to create stasis thrombi, with tissue harvest at either 8 or 21 days. Tissue analysis included gene expression of vascular smooth muscle cells (alpha smooth muscle actin [aSMA], SM22) and endothelial marker (CD31), by real-time polymerase chain reaction, enzyme-linked immunosorbent assay, matrix metalloproteinase (MMP)-2 and -9 activity by zymography, and vein wall collagen by picro-Sirius red histologic analysis. A P < .05 was considered significant.Results: Thrombi were significantly larger in both 8-day and 21-day uPA -/- as compared with wild type (WT) and were significantly smaller in both 8-day and 21-day PAI-1 - /- as compared with WT. Correspondingly, 8-day plasmin levels were reduced in half in uPA -/- and increased three-fold in PAI-1 - /- when compared with respective WT thrombi (P < .05; n = 5-6). The endothelial marker CD31 was elevated two-fold in PAI-1 -/- mice at 8 days, but reduced 2.5-fold at 21 days in uPA -/- as compared with WT (P = .02; n = 5-6), suggesting less endothelial preservation. Vein wall vascular smooth muscle cell (VSMC) gene expression showed that 8-day and 21-day PAI-1 -/-mice had 2.3- and 3.8-fold more SM22 and 1.8- and 2.3-fold more aSMA expression than respective WT (P < .05; n = 5-7), as well as 1.8-fold increased aSMA ( + ) cells (P< .05; n = 3-5). No significant difference in MMP-2 or -9 activity was found in the PAI-1 - /- mice compared with WT, while 5.4-fold more MMP-9 was present in 21-day WT than 21-dayuPA -/- (P= .03; n = 5). Lastly, collagen was -two-fold greater at8 days in PAI-1 -/- IVC as compared with WT (P = .03; n = 6) with no differences observed in uPA -/- mice.Conclusions: In stasis DVT, plasmin activity is critical for thrombus resolution. Divergent vein wall responses occur with gain or loss of plasmin activity, and despite smaller VT, greater vein wall fibrosis was associated with lack of PAI-1.
机译:目的:深静脉血栓形成(DVT)解决促进炎症反应,导致血管壁损伤和瘢痕形成。尿激酶纤溶酶原激活物(uPA)及其抑制剂纤溶酶原激活物抑制剂1(PAI-1)是纤溶系统不可或缺的组成部分,对于静脉血栓形成(VT)的解决至关重要。该研究确定了暴露于纤溶酶活性升高和降低时的静脉壁反应。方法:uPA-/-或PAI-1-/-小鼠下腔静脉(IVC)连接模型及其遗传野生型(B6 / SvEv和C57 / BL6分别用于产生瘀血栓,在8或21天时收获组织。组织分析包括通过实时聚合酶链反应,酶联免疫吸附测定,基质金属蛋白酶(MMP)-2和血管平滑肌细胞(α平滑肌肌动蛋白[aSMA],SM22)和内皮标记(CD31)的基因表达。酶活法测定-9的活性,并通过picirius-Sirius red组织学分析静脉壁胶原。 AP <.05被认为是显着的。结果:与野生型(WT)相比,uPA-/-在8天和21天的血栓形成均显着较大,而在8天和21天的PAI-中血栓形成均显着较小。 1-/-与WT相比。相应地,与相应的WT血栓相比,uPA-/-的8天纤溶酶水平降低了一半,而PAI-1-/-则升高了三倍(P <.05; n = 5-6)。与WT相比,PAI-1-/-小鼠中的内皮标记CD31在8天时升高了2倍,但在21天时在uPA-/-中则降低了2.5倍(P = .02; n = 5-6) ,提示内皮保存较少。静脉壁血管平滑肌细胞(VSMC)基因表达表明,与相应的WT相比,第8天和第21天PAI-1-/-小鼠的SM22和aSMA的表达分别高2.3和3.8倍(1.8和2.3倍) P <.05; n = 5-7),以及增加了1.8倍的aSMA(+)细胞(P <.05; n = 3-5)。与WT相比,PAI-1-/-小鼠的MMP-2或-9活性没有显着差异,而21天WT中MMP-9的存在量比21天uPA-/-多5.4倍(P = 0.03; n = 5)。最后,PAI-1-/-IVC在第8天的胶原蛋白比野生型(P = .03; n = 6)高出两倍(在uPA-/-小鼠中未观察到差异)。纤溶酶活性对于血栓形成至关重要。随着纤溶酶活性的增加或减少,会发生发散的静脉壁反应,尽管VT较小,但较大的静脉壁纤维化与PAI-1缺乏有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号